I hope someday in the future we are given a comphensive overview of the ampakine platform and what are Respire's viable pursuits. From what I can glean it has mostly been about CX1739- for phase 2 SCI that has not moved in 18 months... and CX717 which had solid ADHD trial results. CX1739 is believed to be superior and probably has better chance in ADHD trials would be my guess but no color yet on what the new grant application for ADHD consists of.
They have published alot and re-capped alot of old data it appears. Is there any new technology or combination therapy to make any old compounds viable or target other indications?
Market Data 
Markets 
AI
